BACKGROUND AND PURPOSE: Warfarin-associated intracerebral hemorrhage (WICH) became more frequent in the past 2 decades. Interest in potential WICH treatment trials has grown, but the practicality of such trials has received less attention. We determined the number of patients that would be eligible for enrollment in hypothetical treatment trials for WICH using a population-based study. METHODS: We identified all patients aged 18 years or older from the Greater Cincinnati/Northern Kentucky region with nontraumatic intracerebral hemorrhage in 2005. Three hypothetical WICH treatment trial criteria sets were used to determine eligibility for enrollment, varying from relatively strict to broadly inclusive. For the hypothetical trials, we assumed the comparison of a standard therapy to an alternative therapy. Sample size calculations assumed different rates of poor outcome depending on the criteria set, various effect sizes, a 2-sided alpha of 0.05, and 80% power. Given 5 years of trial enrollment, the population base needed to enroll the required subjects was then calculated. RESULTS: Warfarin-associated intracerebral hemorrhage accounted for 54 of 286 (19%) cases of intracerebral hemorrhage within the Greater Cincinnati/Northern Kentucky region in 2005. Eligibility rates ranged from 2 of 54 WICH patients (4% of cases, strictest set) to 11 of 54 WICH patients (20% of cases, most inclusive set). Given these rates, a population base of at least 67 million persons would be required to conduct a 5-year trial for WICH with a 10% effect size using a moderately strict criteria set. CONCLUSIONS: Any planned treatment trial for WICH should anticipate significant challenges in successfully enrolling adequate numbers of patients.
BACKGROUND AND PURPOSE:Warfarin-associated intracerebral hemorrhage (WICH) became more frequent in the past 2 decades. Interest in potential WICH treatment trials has grown, but the practicality of such trials has received less attention. We determined the number of patients that would be eligible for enrollment in hypothetical treatment trials for WICH using a population-based study. METHODS: We identified all patients aged 18 years or older from the Greater Cincinnati/Northern Kentucky region with nontraumatic intracerebral hemorrhage in 2005. Three hypothetical WICH treatment trial criteria sets were used to determine eligibility for enrollment, varying from relatively strict to broadly inclusive. For the hypothetical trials, we assumed the comparison of a standard therapy to an alternative therapy. Sample size calculations assumed different rates of poor outcome depending on the criteria set, various effect sizes, a 2-sided alpha of 0.05, and 80% power. Given 5 years of trial enrollment, the population base needed to enroll the required subjects was then calculated. RESULTS:Warfarin-associated intracerebral hemorrhage accounted for 54 of 286 (19%) cases of intracerebral hemorrhage within the Greater Cincinnati/Northern Kentucky region in 2005. Eligibility rates ranged from 2 of 54 WICH patients (4% of cases, strictest set) to 11 of 54 WICH patients (20% of cases, most inclusive set). Given these rates, a population base of at least 67 million persons would be required to conduct a 5-year trial for WICH with a 10% effect size using a moderately strict criteria set. CONCLUSIONS: Any planned treatment trial for WICH should anticipate significant challenges in successfully enrolling adequate numbers of patients.
Authors: Stephan A Mayer; Nikolai C Brun; Kamilla Begtrup; Joseph Broderick; Stephen Davis; Michael N Diringer; Brett E Skolnick; Thorsten Steiner Journal: N Engl J Med Date: 2005-02-24 Impact factor: 91.245
Authors: Matthew L Flaherty; Daniel Woo; Mary Haverbusch; Padmini Sekar; Jane Khoury; Laura Sauerbeck; Charles J Moomaw; Alexander Schneider; Brett Kissela; Dawn Kleindorfer; Joseph P Broderick Journal: Stroke Date: 2005-03-24 Impact factor: 7.914
Authors: Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; James B Seward; Kent R Bailey; Toshiji Iwasaka; Teresa S M Tsang Journal: Stroke Date: 2005-10-13 Impact factor: 7.914
Authors: Arne Lauer; Flor A Cianchetti; Elizabeth M Van Cott; Frieder Schlunk; Elena Schulz; Waltraud Pfeilschifter; Helmuth Steinmetz; Chris B Schaffer; Eng H Lo; Christian Foerch Journal: Circulation Date: 2011-09-12 Impact factor: 29.690
Authors: Arne Lauer; Waltraud Pfeilschifter; Chris B Schaffer; Eng H Lo; Christian Foerch Journal: Lancet Neurol Date: 2013-03-18 Impact factor: 44.182
Authors: Adrian R Parry-Jones; Mario Di Napoli; Joshua N Goldstein; Floris H B M Schreuder; Sami Tetri; Turgut Tatlisumak; Bernard Yan; Koen M van Nieuwenhuizen; Nelly Dequatre-Ponchelle; Matthew Lee-Archer; Solveig Horstmann; Duncan Wilson; Fulvio Pomero; Luca Masotti; Christine Lerpiniere; Daniel Agustin Godoy; Abigail S Cohen; Rik Houben; Rustam Al-Shahi Salman; Paolo Pennati; Luigi Fenoglio; David Werring; Roland Veltkamp; Edith Wood; Helen M Dewey; Charlotte Cordonnier; Catharina J M Klijn; Fabrizio Meligeni; Stephen M Davis; Juha Huhtakangas; Julie Staals; Jonathan Rosand; Atte Meretoja Journal: Ann Neurol Date: 2015-05-14 Impact factor: 10.422